Technology is a valuable tool for scientists and doctors to come together to treat cancer. Scientists are in the early trial stages of testing a newly developed implant to monitor and treat cancer in real time. A group of scientists are making groundbreaking progress in nanomedicines to treat cancer and other diseases. A new blood test has been developed to detect early-stage ovarian cancer with the hope of improving outcomes for patients.
Scientists Developing Implant to Cure Cancer in Just 60 Days- with Goal to Slash Death Rates by 50%
Curing cancer could soon be as easy as a few taps on your mobile, according to a team of scientists at Rice University who have received $45 million and funding a for a novel, implant-based treatment system that could cut cancer death rates by 50% reports New York Post. Scientists are trying to improve immunotherapy treatment with the use of an implanted device. The device will monitor the patient’s cancer and make the needed changes to the immunotherapy dose immediately. This device is a closed loop system that is chargeable and can communicate wirelessly. It provides real time information from the cancerous tumors inside the patient, allowing for quicker changes to the treatments. This implant is designed for peritoneal cancers such as pancreas, liver, and lung cancers. The first trial of this device is being tested on ovarian cancer; scientists hope for human trials within five years. Click here for the full story.
University of Delaware Researchers Develop Groundbreaking Nanomedicines for Cancer and Other Diseases
The University of Delaware’s researchers, led by associate professor Emily day, are working on novel nanomedicines. These are aimed at treating diseases such as cancer, blood disorders, and reproductive health conditions reports University of Delaware. The nanoparticles have specific chemical properties to help avoid being noticed by the immune system. They are sent to specific target cells to deliver treatment. This method of treatment helps reduce the required dose and decreases damage to healthy tissues. Scientists have made nanoparticles coated in biological materials like antibodies to help evade the immune system. This team of scientists is studying the use of this treatment to for other diseases besides cancer. Click here for the full story.
New Blood Test Detects Early-Stage Ovarian Cancer
High-grade serious ovarian carcinoma (HGSOC) is the most common type of ovarian cancer. It is also the most lethal form, in part because clinicians do not have effective ways to screen women for it during the cancer’s early stages, when it’s easiest to treat reports Technology Networks. With ovarian cancer, it is hard to detect a lump in the pelvis and difficult to do a biopsy. This makes it more difficult for doctors to choose a treatment option. This new test is a liquid biopsy using blood to determine if a pelvic mass is benign or cancerous. This test gives doctors more information prior to surgery, helping them to choose the best treatment. OvaPrintTM is the name of this new blood test. Scientists are hoping to use this as a screening tool to catch ovarian cancer early, leading to better patient outcomes. OvaPrintTM is testing the blood for a modification of DNA that is a biomarker for ovarian cancer. Scientists have used machine learning to develop a way to distinguish between benign and cancerous samples with very high accuracy. They are in the process of further studies before releasing the test for clinical use. Click here for the full story.
Dana Kaiser is a professional writer and a strong patient advocate, learning from experience during her 22-year career as a nurse.